Lead investor is Virginia Life Science Investments

Rehovot, Israel and Richmond, VA September  6, 2011 – ImmunArray, developer of the iChip, a groundbreaking in-vitro auto antibody detection technology, is pleased to announce the addition of D. Scott Batty Jr., MD to the executive management team. Dr. Batty will assume the position of EVP and his initial focus will be to direct and accelerate the company’s expanding experience and capabilities in support of selected Pharmaceutical Company Alliances. These capabilities will enhance the Pharma partners’ competitive positioning via a variety of applications. The iChip technology can be used to analyze likely responders in both clinical trials and clinical use, personalizing the use of the Partner’s compound to a population most likely to benefit.  The iChip can also be utilized to optimize manufacturing processes, select best of class analogues, differentiate competitive compounds or defend against generic entrants by demonstrating tangible clinical differences in effectiveness. In addition, the technology can be developed in a broad array of diagnostic capabilities, from companion diagnostics during clinical development to new tools for clinicians to better focus therapy for each individual patient.

Following a residency in General Surgery at Walter Reed Army Medical Center, Dr. Batty was trained as a multi-organ transplant surgeon at the University of Pittsburgh.  After transitioning to industry, Dr. Batty has held a number of prominent roles, having most recently managed Medical Affairs for a multi-product Immunosupressive and Oncology portfolio for a leading Pharmaceutical company.   In addition to this important expansion of management capabilities, Virginia Life Science Investments, LLC. (VLSI) has increased its investment in the company.

Donna J. Edmonds, ImmunArray’s Chairperson and CEO of the Virginia BioSciences Commercialization Center, the VLSI’s operating subsidiary, states: “We view Immunarray as a very key technology in the rapidly changing healthcare environment. It offers the field an advanced and unique capability by using the immune system as a source of critical information about the state of the body. It enables a wide range of applications to help reduce costs and improve care in both the diagnostic and pharmaceutical markets. Dr. Batty’s experience as a practicing surgeon and most recently as an industry executive is a very important addition to the company’s leadership as it enters its commercial phase of operations.”

About ImmunArray:

ImmunArray, founded in 2006, holds an exclusive, worldwide license from the Weizmann Institute of Science to develop and commercialize the iChip technology originally  developed at the Weizmann Institute in Rehovot by the world-renowned immunologist Prof. Irun Cohen. The Company is developing a series of novel tests for early diagnosis of immune-related disorders and continues a funded collaborative R&D program with a major pharmaceutical company to support its drug portfolio and  enhance the patented technology for individual pre-screening of therapeutic regimens.  ImmunArray's Chief Executive Officer, Eli Sahar, PhD., brings over 25 years of experience in the field of in-vitro diagnostics. The company is privately held.  For more information:  www.immunarray.com

 About VLSI:

Virginia Life Science Investments is a business development company that invests in promising primarily off-shore, life science companies. The portfolio is currently focused on companies that specialize in technologies that support  medical device and diagnostics development,  ranging from simple devices through platform technologies.  The VLSI’s wholly owned subsidiary, VBCC, provides services that accelerate the development and growth of these bioscience companies, helping to mitigate risk and increase overall valuation.  The goal to reduce investment risk by assuring the commercialization of the various technologies is efficiently and effectively managed with VBCC serving as a strategic partner.  The VLSI was founded in 2009 and is a for-profit company, supported by private capital. For more information: www.vbcc-inc.com